There is urgent need for reliable experimental models in order to improve the chemotherapeutic treatment of head and neck cancer. Such models may provide a rationale for the incorporation of established and new cytostatic agents in clinical trials.
The nude mouse xenograft model seems suitable for the evaluation of anticancer drugs. Xenografted tumours generally respond to agents that are active in the clinic (Shorthouse et al., 1982; Steel et al., 1983) . Moreover, positive correlations between chemosensitivity of xenografts and their source tumours have been described (Nowak et al., 1978; Osieka, 1984; Fiebig et al., 1984) . As a drawback, in vivo testing with xenografted tumours can be very time-consuming and expensive.
Soft agar clonogenic assays appear to be promising in vitro models for chemosensitivity testing (Tveit et al., 1982; Salmon, 1984) . However, culturing cells obtained from squamous cell carcinomas of the head and neck (H&N) region has been rather unsuccessful due to high contamination rates, small cell yields, low growth rates and low cloning efficiencies (Johns & Mills, 1983 ; Mattox et al., 1984; Cobleigh et al., 1984 Heinerman et al., 1985) . Recently we reported that 79% of head and neck tumours growing in nude mice could be cultured in the clonogenic assay with a relatively high cloning efficiency making drug testing possible (Heinerman et al., 1985) . In the present study we investigated the potential of the combination of the nude mouse xenograft model and the clonogenic assay for the selection of chemotherapeutic agents active against head and neck cancer.
Materials and methods

Xenografts
Xenografts were grown in female nude mice (B1O.LP/Cpb, 8-10 weeks old, Centraal Proefdierenbedrijf TNO, Zeist, the Netherlands). Tumour specimens from previously untreated patients were aseptically removed, slices measuring 3 x 3 x 1 mm were dissected and implanted s.c. in the lateral thoracic region of the test mouse (Braakhuis et al., 1983) . The xenograft HNX-Hep-2 was obtained by s.c. injection of 3 x 106 cells of the cell line Hep-2 (Gibco), established from a human squamous cell carcinoma of the larynx (Moore et al., 1955) . In addition, the rat rhabdomyosarcoma RI was obtained from TNO (Rijswijk, the Netherlands) as a solid tumour and xenografted.
Tumour volume was calculated as length x width x height x 0.5 (Looney et al., 1973 Clonogenic assay Tumours were minced into millimeter pieces with scalpel blades and treated for 2 h with 0.2% collagenase (150 U mg-1, type II, Worthington) in McCoy's 5A medium containing 10% heat inactivated foetal calf serum (FCS, Gibco), penicillin (10OUml-1) and streptomycin (100ugml-'). Subsequently, the tissue was carefully filtered without pressure through a 40 mesh wire screen to prepare a single cell suspension. Cells were cultured in a bilayer agar system as described by Hamburger and Salmon (1977) , except that no mercaptoethanol and conditioned medium were added, while horse serum was replaced by FCS. In brief, the underlayer consisted of enriched McCoy's 5A with 15% FCS and 0.5% agar, the upper layer of enriched CMRL (Gibco) with 15% FCS and 0.3% agar. Drug sensitivity assays were performed by continuous exposure of 3 x 105 cells/plate (H &N cancer xenografts) or 0.2 x 105 cells/plate (RI tumour) to 3 concentrations of each drug with a 10-log interval. Drug testing was performed at clinically relevant concentrations derived from a previous report (Alberts & Chen, 1980) . For Cy the peak plasma concentration of 4-hydroxy-cyclophosphamide, the active metabolite of mafosfamide and Cy (Hilgard & Brock, 1984) In vivo studies Chemotherapy of tumour xenografts growing subcutaneously in athymic nude mice was performed as described previously (Braakhuis et al., 1983) . Briefly, chemotherapy was started when, the tumours reached 100 mm3 (range 50-150 mm3). The tumours were randomly divided into treatment and control groups, each group consisting of at least 5 tumours. Drugs were administered i.p. in a maximum tolerated dose, i.e. the maximum weight loss of the mice was 15%. The following schedules were used: BLM: 15mg kg-1 daily for 3 days, CDDP: 3mg kg-1 daily for 3-4 days, Dox: 8mgkg' on days 1 and 8, 5-FU: 25mgkg-1 daily for 4 days, MTX: 5mg kg-1 for 5 days, VCR: lmgkg-1 daily for 2 days. Growth delay induced by treatment was defined as the difference between the mean values of the time required by tumours of treated and control animals to double their volume, divided by the mean value of the time needed by the control mice to double their volume. Growth delay was thus expressed in terms of the fold increase in volume doubling time gained by the treatment. The mean values of doubling times of control and treated tumours were compared with a one-way analysis of variance, followed by the Student-Newman-Keuls-test (Sokal & Rohlf, 1969 Table I. drugs. Up to now we were able to test 6 xenograft lines with 3 to 7 drugs in vivo (Table III) 
Discussion
Human head and neck cancers, transplanted and growing in athymic nude mice can be cultured in the clonogenic assay with a high success rate. This is in sharp contrast to head and neck tumours obtained directly from patients where small yields, low growth rates, low cloning efficiencies and high contamination rates limits the applicability of the clonogenic assay for drug sensitivity studies (Johns & Mills, 1983; Mattox et al., 1984; Cobleigh et al., 1984; Heinerman et al., 1985) . Moreover, as illustrated in the present study, xenografts provide enough cells to test at least 24 drugs or drug concentrations, and drug testing can be repeated.
An inhibition of more than 50% by continuous exposure of 1/10 of the peak plasma concentration was observed in 7 out of 48 (14.6%) of the head and neck cancers. This is in agreement with results obtained with tumours from various sites, taken directly from patients (Bertelsen et al., 1984; Von Hoff et al., 1983; Shoemaker et al., 1985) .
In vivo treatment of head and neck tumour bearing nude mice showed that growth of all xenograft lines tested could be delayed by at least one anticancer drug. However, except for 1 head and neck tumour line, highly sensitive to treatment with BLM, a growth delay exceeding 2 was never observed. In order to avoid extensive time-consuming in vivo testing, the clonogenic assay might be helpful to select potentially active drugs for H&N cancer. To use this assay for drug screening it is important to know whether the in vitro results correctly predict the in vivo results. Based on our experiments the clonogenic assay would have correctly predicted sensitivity in 4 out of 6 (66.7%) and resistance in 21/26 (80.8%) of the cases. For BLM, CDDP, VCR and Dox the overall correlation was 100%, although for the two latter drugs only 3 correlations could be made. Positive correlations between drug sensitivity and resistance of human tumour xenografts in the nude mouse xenograft model and the clonogenic assay have been reported previously (Bateman et al., 1980; Taetle et al., 1982; Tveit et al., 1980; Zirvi et al., 1983; Friedman et al., 1984) . However, for Dox, the in vitro activity was not reflected by an in vivo delay of tumour growth (Bateman et al., 1980) , which is not in agreement with the results of Taetle et al. (1982) and those reported in this paper. Also for some analogues of Dox a significant negative correlation between the results in the clonogenic assay and nude mice was reported (Taetle et al., 1982) .
A number of problems are associated with in vivo-in vitro correlations (Selby et al., 1983; Singletary et al., 1985; Twentyman, 1985) . Growth delay in vivo depends upon the cytostatic drug dose, the schedule of treatment as well as the pharmacokinetics in nude mice. Moreover, growth delay may not only reflect kill of clonogenic cells but also of other tumour cells and non-tumour cells. On the other hand, inhibition of colony growth depends on the drug concentration, the exposure time and stability of drugs in vitro. The lack of correlation between in vivo and in vitro sensitivity in the present study for Cy (RI tumour) and 5-FU (all tumour lines) may be connected with the above mentioned problems. In addition, the complete ineffectiveness of 5-FU in the nude mouse model may well be related to a relatively low peak plasma level in this species as compared to the human situation (Inaba et al., 1984) . The ineffectiveness of MTX in vitro in the present study may be due to the presence of nucleobases in the culture media (Umbach et al., 1984) . Indeed we recently found for the MTXsensitive RI tumour that a complete inhibition of colony growth could be obtained at a concentration of 0.05 jug MTX ml-1 by using nucleoside-free culture media and dialysed fetal bovine serum (unpublished results).
A number of problems have to be solved before the clonogenic assay can be applied to predict the sensitivity of an individual patient's tumour (Von Hoff et al., 1984) . Recently it was reported that this system may play a useful additional role in the testing of new drugs (Shoemaker et al., 1985) . The use of xenografts as a tumour source gives some advantages over the use of patient's tumours. The plating efficiencies are higher in xenografts than in patient's tumours, especially for H & N cancer (Heinerman et al., 1985) . With xenografts drug testing can be reproducible, repeated and can be related directly to in vivo testing in the nude mouse.
The clonogenic assay can be used to select new drugs for subsequent testing in the nude mouse. Our results with established drugs indicate that the clonogenic assay predicted sensitivity and resistance in a majority of cases. Due to the lack of correlation between in vitro and in vivo sensitivity for some drugs, one has to be aware that combination of these models will have limitations, when it is used in the screening of new drugs.
